# Biotech Daily Digest â€” 2026-02-18

**30 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 8 items
- Fierce Biotech: 7 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 13 items


## Eli Lilly Press Releases

- **[Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight](https://investor.lilly.com/news-releases/news-release-details/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-0)**  
  _Wed, 18 Feb 2026 06:45:00 -0500_  
  At 36 weeks inÂ the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and â‰¥10% weight loss In a key secondary endpoint, patients taking Taltz and Zepbound were 40% more likely to achieve PASI


## Endpoints News

- **[Faeth goes public in merger with Sensei, nets $200M in stock sale](https://endpoints.news/faeth-goes-public-in-merger-with-sensei-nets-200m-in-stock-sale/)**  
  _Wed, 18 Feb 2026 13:00:57 +0000_  
  Sensei Biotherapeutics has bought the cancer metabolism startup Faeth Therapeutics in an all-stock deal that has the hallmarks of a reverse merger, and raised $200 million as part of a private placement, the company announced ...

- **[FDA reverses course, will review Modernaâ€™s flu vaccine](https://endpoints.news/fda-reverses-course-will-review-modernas-flu-vaccine/)**  
  _Wed, 18 Feb 2026 12:45:45 +0000_  
  Moderna said that the FDA will review the companyâ€™s flu vaccine after all, now that the two sides agreed to an amended filing.

 The company said Wednesday that following a type ...

- **[Lilly licenses CSLâ€™s IL-6 immuno-inflammatory antibody for $100M upfront](https://endpoints.news/lilly-licenses-csls-il-6-immuno-inflammatory-antibody-for-100m-upfront/)**  
  _Wed, 18 Feb 2026 11:31:31 +0000_  
  CSL will need more than $100 million to recover from its current difficulties, but itâ€™s a start.

 Eli Lilly has paid the nine-figure sum upfront for rights to the Australian companyâ€™s anti ...

- **[Paragon's new biotech Korsana tackles Alzheimer's like Roche](https://endpoints.news/paragons-new-biotech-korsana-tackles-alzheimers-like-roche/)**  
  _Wed, 18 Feb 2026 11:00:57 +0000_  
  Biologics maker Paragon Therapeutics has spun out its seventh biotech startup, this time in pursuit of Roche in the fight against Alzheimer's.

 Like Roche with trontinemab, Korsana Biosciences is attempting to deliver an antibody that ...

- **[Moderna faces setback in Arbutus' mRNA patent fight](https://endpoints.news/moderna-faces-setback-in-arbutus-mrna-patent-fight/)**  
  _Tue, 17 Feb 2026 20:36:05 +0000_  
  

- **[Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters](https://endpoints.news/six-biotechs-file-for-hkex-listing-faraday-pharmaceuticals-shutters/)**  
  _Tue, 17 Feb 2026 15:52:53 +0000_  
  Plus, news about Cyrano, Sanofi and Teva's duvakitug, Rocheâ€™s Gazyva, Eli Lilly's Retevmo, Johnson & Johnsonâ€™s Rybrevant, Newron Pharmaceuticals, and Gelmedix:

 ðŸ‡­ðŸ‡° Six biotechs target HKEX listing: Novlead Biotechnology ...

- **[Compass Pathways soars on second Phase 3 depression hit](https://endpoints.news/compass-pathways-soars-on-second-phase-3-depression-hit/)**  
  _Tue, 17 Feb 2026 15:38:26 +0000_  
  The second pivotal trial of Compass Pathwaysâ€™ psilocybin formulation for treatment-resistant depression has succeeded, the company said Tuesday, a result that could help the drug gain approval next year.

 The first approval trial of the ...

- **[Ocular Therapeutixâ€™ Axpaxli shows superiority over Eylea, shares sink](https://endpoints.news/ocular-therapeutixs-axpaxli-could-become-first-choice-in-wet-amd-after-showing-superiority-over-eylea/)**  
  _Tue, 17 Feb 2026 12:05:11 +0000_  
  Ocular Therapeutixâ€™ investigational drug could become the preferred therapy for wet age-related macular degeneration after data released Tuesday showed statistical superiority to Regeneron and Bayerâ€™s current bestseller Eylea.

 However, the data from the trial appear ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/fda-accepts-filing-moderna-flu-vaccine-after-swift-u-turn" hreflang="en">FDA accepts filing for Moderna flu vaccine after swift rethink</a>](https://www.fiercebiotech.com/biotech/fda-accepts-filing-moderna-flu-vaccine-after-swift-u-turn)**  
  _Feb 18, 2026 8:51am_  
  The FDA has accepted Modernaâ€™s revised influenza vaccine filing days after controversially refusing to review the original submission, putting the biotech on track to win approval in time for the 2026-27 flu season.

- **[<a href="https://www.fiercebiotech.com/biotech/preclinical-eye-disease-biotech-sets-sights-17m-nyse-ipo" hreflang="en">Preclinical eye disease biotech sets sights on $17M NYSE IPO</a>](https://www.fiercebiotech.com/biotech/preclinical-eye-disease-biotech-sets-sights-17m-nyse-ipo)**  
  _Feb 18, 2026 8:31am_  
  EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-pays-csl-100m-upfront-il-6-antibody-flunked-phase-3-organ-transplant-study" hreflang="en">Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study</a>](https://www.fiercebiotech.com/biotech/lilly-pays-csl-100m-upfront-il-6-antibody-flunked-phase-3-organ-transplant-study)**  
  _Feb 18, 2026 5:09am_  
  Eli Lilly is paying $100 million upfront for the right to develop CSLâ€™s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.

- **[<a href="https://www.fiercebiotech.com/cro/immunology-cro-roukenbios-partnership-avs-bio-aims-more-predictable-and-efficient-antibody" hreflang="en">Immunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody development</a>](https://www.fiercebiotech.com/cro/immunology-cro-roukenbios-partnership-avs-bio-aims-more-predictable-and-efficient-antibody)**  
  _Feb 17, 2026 2:43pm_  
  Preclinical CRO RoukenBio has inked a partnership with Connecticut-based biologics supplier AVS Bio that aims to leverage each others' strengths to avoid late-stage trial failures and boost therapeutic antibody development.

- **[<a href="https://www.fiercebiotech.com/biotech/boehringer-axes-inhaled-gene-therapy-after-viewing-cystic-fibrosis-data" hreflang="en">Boehringer axes inhaled gene therapy after viewing cystic fibrosis data</a>](https://www.fiercebiotech.com/biotech/boehringer-axes-inhaled-gene-therapy-after-viewing-cystic-fibrosis-data)**  
  _Feb 17, 2026 12:34pm_  
  Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis after terminating a phase 1/2 trial.

- **[<a href="https://www.fiercebiotech.com/biotech/cell-therapy-company-set-end-tokyo-biotech-ipo-drought-92m-offering" hreflang="en">Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering</a>](https://www.fiercebiotech.com/biotech/cell-therapy-company-set-end-tokyo-biotech-ipo-drought-92m-offering)**  
  _Feb 17, 2026 10:19am_  
  Japan-based cell therapy company Innovacell is planning to end a drought of biotech IPOs on the Tokyo Stock Exchange next week, the businessâ€™ CEO has confirmed.

- **[<a href="https://www.fiercebiotech.com/biotech/cyrano-noses-toward-pivotal-trial-after-midphase-smell-loss-win" hreflang="en">Cyrano noses toward pivotal trial after midphase smell loss win</a>](https://www.fiercebiotech.com/biotech/cyrano-noses-toward-pivotal-trial-after-midphase-smell-loss-win)**  
  _Feb 17, 2026 9:58am_  
  Cyrano Therapeutics is savoring a phase 2 victory. With the Flavor study hitting its primary endpoint, the biotech is preparing to take its treatment for persistent smell loss into phase 3 in the second half of the year.


## Regeneron Press Releases

- **[Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)](https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-tessera-therapeutics-jointly-develop-tsra-196)**  
  _Mon, 01 Dec 2025 07:00:00 -0500_  
  TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million , inclusive of a cash upfront and equity investment from Regeneron ; companies to share


## arXiv q-bio

- **[Household size can explain 40% of the variance in cumulative COVID-19 incidence across Europe](https://arxiv.org/abs/2602.15447)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2602.15447v1 Announce Type: new 
Abstract: Household size impacts the spread of respiratory infectious diseases: Larger households tend to boost transmission by acquiring external infections more frequently and subsequently transmitting them back into the community. Furthermore, mandatory interventions primarilyâ€¦

- **[Molecular Design beyond Training Data with Novel Extended Objective Functionals of Generative AI Models Driven by Quantum Annealing Computer](https://arxiv.org/abs/2602.15451)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2602.15451v1 Announce Type: new 
Abstract: Deep generative modeling to stochastically design small molecules is an emerging technology for accelerating drug discovery and development. However, one major issue in molecular generative models is their lower frequency of drug-like compounds. To resolve this problem,â€¦

- **[Relating biomarkers and phenotypes using dynamical trap spaces](https://arxiv.org/abs/2602.15691)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2602.15691v1 Announce Type: new 
Abstract: Connecting the dynamics of biomolecular networks to experimentally measurable cell phenotypes remains a central challenge in systems biology. Here we introduce a model-based definition of phenotype as a partial steady state that is committed to a certain dynamical outcoâ€¦

- **[Energy budgets govern synaptic precision and its regulation during plasticity](https://arxiv.org/abs/2602.15787)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2602.15787v1 Announce Type: new 
Abstract: Synaptic transmission must balance the need for reliable signalling against the metabolic cost of achieving that reliability. How energetic constraints shape synaptic precision and its regulation during plasticity remains unclear. Here we develop an energy--constrainedâ€¦

- **[Scaling Laws for Masked-Reconstruction Transformers on Single-Cell Transcriptomics](https://arxiv.org/abs/2602.15253)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2602.15253v1 Announce Type: cross 
Abstract: Neural scaling laws -- power-law relationships between loss, model size, and data -- have been extensively documented for language and vision transformers, yet their existence in single-cell genomics remains largely unexplored. We present the first systematic study ofâ€¦

- **[A golden-ratio partition of information and the balance between prediction and surprise: a neuro-cognitive route to antifragility](https://arxiv.org/abs/2602.15266)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2602.15266v1 Announce Type: cross 
Abstract: Adaptive systems must strike a balance between prediction and surprise to thrive in uncertain environments. We propose an information-theoretic balance function, $ f(p) = -(1 - p)\ln(1 - p) + \ln p $, which quantifies the net informational gain from contrasting explaiâ€¦

- **[MRC-GAT: A Meta-Relational Copula-Based Graph Attention Network for Interpretable Multimodal Alzheimer's Disease Diagnosis](https://arxiv.org/abs/2602.15740)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2602.15740v1 Announce Type: cross 
Abstract: Alzheimer's disease (AD) is a progressive neurodegenerative condition necessitating early and precise diagnosis to provide prompt clinical management. Given the paramount importance of early diagnosis, recent studies have increasingly focused on computer-aided diagnosâ€¦

- **[A Foundational Theory for Decentralized Sensory Learning](https://arxiv.org/abs/2503.15130)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2503.15130v2 Announce Type: replace 
Abstract: In both neuroscience and artificial intelligence, popular functional frameworks and neural network formulations operate by making use of extrinsic error measurements and global learning algorithms. Through a set of conjectures based on evolutionary insights on the oâ€¦

- **[Multimodal Integrated Knowledge Transfer to Large Language Models through Preference Optimization with Biomedical Applications](https://arxiv.org/abs/2505.05736)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2505.05736v2 Announce Type: replace 
Abstract: The scarcity of high-quality multimodal biomedical data limits the ability to effectively fine-tune pretrained Large Language Models (LLMs) for specialized biomedical tasks. To address this challenge, we introduce MINT (Multimodal Integrated kNowledge Transfer), a fâ€¦

- **[A cell-level model to predict the spatiotemporal dynamics of neurodegenerative disease](https://arxiv.org/abs/2508.15046)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2508.15046v2 Announce Type: replace 
Abstract: A central challenge in modeling neurodegenerative diseases is connecting cellular-level mechanisms to tissue-level pathology, in particular to determine whether pathology is driven primarily by cell-autonomous triggers or by propagation from cells that are already iâ€¦

- **[OpenAIs HealthBench in Action: Evaluating an LLM-Based Medical Assistant on Realistic Clinical Queries](https://arxiv.org/abs/2509.02594)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2509.02594v2 Announce Type: replace 
Abstract: Evaluating large language models (LLMs) on their ability to generate high-quality, accurate, situationally aware answers to clinical questions requires going beyond conventional benchmarks to assess how these systems behave in complex, high-stakes clinical scenariosâ€¦

- **[Lesion-Independent Associations Between Thalamic Nuclei Volumes and Information Processing Speed in Multiple Sclerosis](https://arxiv.org/abs/2511.21677)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2511.21677v2 Announce Type: replace 
Abstract: Background: Cognitive impairment in multiple sclerosis (MS) is driven by both focal inflammation and compartmentalized neurodegeneration, yet the relative effect of lesion-independent thalamic atrophy on information processing speed (IPS) remains unclear. Methods: Tâ€¦

- **[New sector morphologies emerge from anisotropic colony growth](https://arxiv.org/abs/2405.19478)**  
  _Wed, 18 Feb 2026 00:00:00 -0500_  
  arXiv:2405.19478v2 Announce Type: replace-cross 
Abstract: Competition during range expansions is of great interest from both practical and theoretical view points. Experimentally, range expansions are often studied in homogeneous Petri dishes, which lack spatial anisotropy that might be present in realistic populatioâ€¦
